Litcius/Paper detail

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Philip J. Mease, Proton Rahman, Alice B. Gottlieb, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, Désirée van der Heijde, Iain B. McInnes

2020The Lancet344 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePsoriatic arthritisPlaceboInternal medicineClinical endpointRheumatologyArthritisPlacebo-controlled studyClinical trialGastroenterologyDouble blindPathologyAlternative medicineSpondyloarthritis Studies and TreatmentsPsoriasis: Treatment and PathogenesisRheumatoid Arthritis Research and Therapies
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial | Litcius